MTOR and ovarian cancer: To conclude, data reported in this manuscript demonstrate that the pan-AKT inhibitor, GSK2141795, modulates multiple components of AKT signalling in platinum-resistant ovarian cancer cells, most notably components of the mTOR pathway, that [18F]FDG uptake could be used as a non-invasive pharmacodynamic marker and that levels of AKT pathway proteins identified in pre-clinical models, are able to predict CA125 response in platinum resistant ovarian cancer patients treated with the AKT inhibitor GSK2141795.